Latest:
Acimtamig Plus Allogeneic Natural Killer Cells Under Phase 2 Evaluation in R/R Hodgkin Lymphoma and CD30+ PTCL
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest:
Acimtamig Plus Allogeneic Natural Killer Cells Under Phase 2 Evaluation in R/R Hodgkin Lymphoma and CD30+ PTCL
Latest:
Dr Chehrazi-Raffle on Tivozanib With/Without Nivolumab in Metastatic RCC
Latest:
EHA 2025 Insights: DREAMM-7 and DREAMM-8 Trial Updates on Belantamab-Based Regimens for R/R MM
Latest:
Dr Zhang on the Rationale for Investigating Sintilimab/Axitinib in FH-Deficient RCC
Latest:
PD-L1 Status Stratifies Immunotherapy Treatment in NSCLC
Latest:
Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
Latest:
Real-World (RW) Systemic Treatment Patterns in US Patients (PTS) With Hepatocellular Carcinoma (HCC) 2020–2022
Latest:
Dr Schlechter on Updated Data for Botensilimab Plus Balstilimab in MSS mCRC